- $56.06m
- $38.98m
- $0.03m
Talphera Inc expected to post a loss of 20 cents a share - Earnings Preview
Talphera Inc reports results for the quarter ended in January - Earnings Summary
Talphera Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Talphera Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Talphera Inc reports results for the quarter ended in March - Earnings Summary
Talphera Inc reports results for the quarter ended in December - Earnings Summary
Brief: Talphera Announces Fourth Quarter 2023 Financial Results
Brief: Talphera Announces Reduction In Size Of Its Board
Brief: Acelrx Announces Rebranding With Name Change To Talphera Inc
Brief: Acelrx Pharmaceuticals Announces Publication Of Study Evaluating Anticoagulation Practices For Continuous Renal Replacement Therapy In The United States
Brief: Acelrx Pharmaceuticals Files For Mixed Shelf Offering Of Up To $150 Million
Brief: AcelRx Pharmaceuticals Q3 net income from cont ops USD -1.418 million
Brief: Acelrx Pharmaceuticals - On Oct 18, Received Written Notice From Nasdaq Notifying Co That It Is Not In Compliance With Minimum Bid Price Requirement
Brief: Acelrx Receives Ide Approval For Niyad And Advances To A Single Registration Study
AcelRx slides after FDA refuses 'EUA' tag to blood thinner device
Brief: Acelrx Pharmaceuticals Inc - FDA Determined That Review Of Niyad Eua Is Not A Priority And Has Therefore Declined To Issue An Eua For Niyad
AcelRx Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
AcelRx Pharmaceuticals Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: AcelRx Pharmaceuticals Announces Closing Of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules